Anna Keramida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anna Keramida has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Anastasios Bonakis
2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
5 shared publications - Panagiota-Eleni Tsalouchidou
Second Department of Neurology Attikon University Hospital, National and Kapodistrian University of Athens Athens Greece
5 shared publications - Georgios Tsivgoulis
Second Department of Neurology, National and Kapodistrian University of Athens, Attikon University Hospital, Greece (G.T.).
4 shared publications - Katerina Poprelka
First Department of Neurosurgery, Evangelismos Hospital, National & Kapodistrian University of Athens, Athens, Greece
4 shared publications Vasiliki Kotsali-Peteinelli
4 shared publicationsKonstantina Stavrogianni
3 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1744
Brivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence
Background: Brivaracetam (BRV) is a synaptic vesicle protein 2A (SV2A) ligand approved for the treatment of focal-onset seizures. Its clinical use has increasingly expanded beyond approved indications and into understudied populations. Objective: We aim to review BRV use beyond approved indications and in special populations. Methods: MEDLINE, Embase, and Scopus were searched from inception to 30 April 2026. Eligible clinical studies were selected using prespecified criteria and synthesized narratively. Off-label status was determined separately under FDA and EMA labelling. Results: The evidence consisted predominantly of observational studies, real-world cohorts, case series, and subgroup analyses of randomised trials. In genetic generalized epilepsies (GGE), BRV was associated with seizure reduction in several cohorts, whereas findings in developmental and epileptic encephalopathies (DEEs) were more heterogeneous. Real-world studies demonstrated the feasibility of BRV monotherapy, particularly following transition from levetiracetam. In status epilepticus (SE), intravenous BRV has been associated with SE cessation, although its independent contribution, optimal dose and timing, and role in treatment algorithms remain uncertain. Pregnancy and breastfeeding reports identified no clear safety signal, although exposure and long-term outcome data were scarce. Neonatal evidence was restricted largely to pharmacokinetic and short-term tolerability findings. Observational data indicated that psychiatric or behavioural adverse effects did not recur in some patients switched from levetiracetam; evidence in psychotic disorders remained particularly limited. Conclusions: BRV may be useful in selected off-label settings and special populations. However, evidence remains limited and largely observational, so treatment decisions should be individualized. Prospective controlled studies and dedicated registries are needed.
- 3 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1744
Open AccessBrivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence
Background: Brivaracetam (BRV) is a synaptic vesicle protein 2A (SV2A) ligand approved for the treatment of focal-onset seizures. Its clinical use has increasingly expanded beyond approved indications and into understudied populations. Objective: We aim to review BRV use beyond approved indications and in special populations. Methods: MEDLINE, Embase, and Scopus were searched from inception to 30 April 2026. Eligible clinical studies were selected using prespecified criteria and synthesized narratively. Off-label status was determined separately under FDA and EMA labelling. Results: The evidence consisted predominantly of observational studies, real-world cohorts, case series, and subgroup analyses of randomised trials. In genetic generalized epilepsies (GGE), BRV was associated with seizure reduction in several cohorts, whereas findings in developmental and epileptic encephalopathies (DEEs) were more heterogeneous. Real-world studies demonstrated the feasibility of BRV monotherapy, particularly following transition from levetiracetam. In status epilepticus (SE), intravenous BRV has been associated with SE cessation, although its independent contribution, optimal dose and timing, and role in treatment algorithms remain uncertain. Pregnancy and breastfeeding reports identified no clear safety signal, although exposure and long-term outcome data were scarce. Neonatal evidence was restricted largely to pharmacokinetic and short-term tolerability findings. Observational data indicated that psychiatric or behavioural adverse effects did not recur in some patients switched from levetiracetam; evidence in psychotic disorders remained particularly limited. Conclusions: BRV may be useful in selected off-label settings and special populations. However, evidence remains limited and largely observational, so treatment decisions should be individualized. Prospective controlled studies and dedicated registries are needed.
- Open Access
- 27 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Psychological resilience as a key pathway between depression and executive functioning in epilepsy
- 27 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Open AccessPsychological resilience as a key pathway between depression and executive functioning in epilepsy
- Open Access
- 16 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Resilience as a mediating mechanism between psychological distress and quality of life in epilepsy
- 16 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Open AccessResilience as a mediating mechanism between psychological distress and quality of life in epilepsy
- 21 July 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 184
Alexithymia and its relationship with cognition and psychological outcomes in patients with drug-resistant epilepsy
- 21 July 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 184
Alexithymia and its relationship with cognition and psychological outcomes in patients with drug-resistant epilepsy
- Open Access
- 13 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4221
Risk of Diabetes Mellitus in the Myasthenia Gravis: A Systematic Review and Meta-Analysis
Background/Objectives: Myasthenia gravis (MG) comprises an autoimmune disorder marked by muscle weakness and fatigue. MG frequently coexists with other autoimmune conditions, such as diabetes mellitus, which may exacerbate the clinical burden of MG and adversely impact overall quality of life. Methods: This systematic review and meta-analysis aimed to assess the prevalence of diabetes in patients with MG. Following PRISMA guidelines, a comprehensive search was conducted in the MEDLINE PubMed, Scopus, and Google Scholar databases. Results: A total of 11 studies comprising 16,825 patients were included. The pooled prevalence of diabetes among MG patients was 15.6% (95% CI [8.4%, 24.7%]; I2 = 99%, p < 0.001). Compared to healthy controls, MG patients had a 1.24-fold increased risk of developing diabetes (95% CI [1.01–1.54], p < 0.001). Meta-regression showed no association between age and diabetes prevalence, although potential publication bias was noted (Egger’s test, p = 0.72). Conclusions: This meta-analysis reveals a higher prevalence of diabetes among MG patients, with an elevated risk compared to healthy individuals. These findings suggest that the association between MG and diabetes may be mediated by corticosteroid use, genetic factors, and reduced physical activity. The main limitations of this study are the lack of reported data regarding the type of diabetes and patients’ demographic and disease characteristics (MG classification severity and duration and type of treatment). Further studies are needed to investigate the underlying causal mechanisms and to elucidate the relationship between MG and diabetes subtypes.
- 13 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4221
Open AccessRisk of Diabetes Mellitus in the Myasthenia Gravis: A Systematic Review and Meta-Analysis
Background/Objectives: Myasthenia gravis (MG) comprises an autoimmune disorder marked by muscle weakness and fatigue. MG frequently coexists with other autoimmune conditions, such as diabetes mellitus, which may exacerbate the clinical burden of MG and adversely impact overall quality of life. Methods: This systematic review and meta-analysis aimed to assess the prevalence of diabetes in patients with MG. Following PRISMA guidelines, a comprehensive search was conducted in the MEDLINE PubMed, Scopus, and Google Scholar databases. Results: A total of 11 studies comprising 16,825 patients were included. The pooled prevalence of diabetes among MG patients was 15.6% (95% CI [8.4%, 24.7%]; I2 = 99%, p < 0.001). Compared to healthy controls, MG patients had a 1.24-fold increased risk of developing diabetes (95% CI [1.01–1.54], p < 0.001). Meta-regression showed no association between age and diabetes prevalence, although potential publication bias was noted (Egger’s test, p = 0.72). Conclusions: This meta-analysis reveals a higher prevalence of diabetes among MG patients, with an elevated risk compared to healthy individuals. These findings suggest that the association between MG and diabetes may be mediated by corticosteroid use, genetic factors, and reduced physical activity. The main limitations of this study are the lack of reported data regarding the type of diabetes and patients’ demographic and disease characteristics (MG classification severity and duration and type of treatment). Further studies are needed to investigate the underlying causal mechanisms and to elucidate the relationship between MG and diabetes subtypes.
- 18 December 2024
- Published by Springer Nature in Acta Neurologica Belgica
A potentially fatal meningoencephalitis following intramuscular anti-inflammatory injection
- 18 December 2024
- Published by Springer Nature in Acta Neurologica Belgica
A potentially fatal meningoencephalitis following intramuscular anti-inflammatory injection
- Open Access
- 31 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 824
Paraneoplastic Neurological Syndromes as Initial Presentation of Tumors: An Eight-Year Single-Center Experience
Background: Paraneoplastic Neurological Syndromes (PNS) comprise a diverse group of disorders propagated by immune-mediated effects of malignant tumors on neural tissue. Methods: A single-center longitudinal study was performed including consecutive adult patients treated at a tertiary academic hospital between 2015 and 2023 and diagnosed with PNS. PNS were ascertained using the 2004 and the revised 2021 PNS-Care diagnostic criteria. Results: Thirteen patients who fulfilled the 2004 definite PNS criteria were included. PNS comprise diverse neurological syndromes, with neuromuscular junction disorders (54%) and limbic encephalitis (31%) being predominant. PNS-related antibodies were detected in 85% of cases, including anti-AChR (n = 4), anti-P/Q-VGCC (n = 3), anti-Hu (n = 3), anti-Yo (n = 1), anti-Ma (n = 1), anti-titin (n = 1), anti-IgLON5 (n = 1), and anti-GAD65 (n = 1). Thymoma (31%), small-cell lung cancer (23%), and papillary thyroid carcinoma (18%) were the most frequent tumors. Imaging abnormalities were evident in 33% of cases. Early immunotherapy within 4-weeks from symptom onset was associated with favorable outcomes. At a mean follow-up of 2 ± 1 years, two patients with anti-Hu and anti-Yo antibodies died (18%). Four and three patients fulfilled the 2021 PNS-Care diagnostic criteria for definite and probable PNS, respectively. Conclusions: This study highlights the clinical heterogeneity of PNS, emphasizing the need for early suspicion and prompt treatment initiation for optimal outcomes.
- 31 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 824
Open AccessParaneoplastic Neurological Syndromes as Initial Presentation of Tumors: An Eight-Year Single-Center Experience
Background: Paraneoplastic Neurological Syndromes (PNS) comprise a diverse group of disorders propagated by immune-mediated effects of malignant tumors on neural tissue. Methods: A single-center longitudinal study was performed including consecutive adult patients treated at a tertiary academic hospital between 2015 and 2023 and diagnosed with PNS. PNS were ascertained using the 2004 and the revised 2021 PNS-Care diagnostic criteria. Results: Thirteen patients who fulfilled the 2004 definite PNS criteria were included. PNS comprise diverse neurological syndromes, with neuromuscular junction disorders (54%) and limbic encephalitis (31%) being predominant. PNS-related antibodies were detected in 85% of cases, including anti-AChR (n = 4), anti-P/Q-VGCC (n = 3), anti-Hu (n = 3), anti-Yo (n = 1), anti-Ma (n = 1), anti-titin (n = 1), anti-IgLON5 (n = 1), and anti-GAD65 (n = 1). Thymoma (31%), small-cell lung cancer (23%), and papillary thyroid carcinoma (18%) were the most frequent tumors. Imaging abnormalities were evident in 33% of cases. Early immunotherapy within 4-weeks from symptom onset was associated with favorable outcomes. At a mean follow-up of 2 ± 1 years, two patients with anti-Hu and anti-Yo antibodies died (18%). Four and three patients fulfilled the 2021 PNS-Care diagnostic criteria for definite and probable PNS, respectively. Conclusions: This study highlights the clinical heterogeneity of PNS, emphasizing the need for early suspicion and prompt treatment initiation for optimal outcomes.
- 1 December 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 113, 107563
Reproductive health in patients with epilepsy
- 1 December 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 113, 107563
Reproductive health in patients with epilepsy